HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Expression of TCR-zeta chain and apoptosis in subpopulations of tumor-associated lymphocytes (TALs) from malignant pleural effusions.

Abstract
Malignant effusions in serous cavities represent suspension of tumors and inflammatory cells and therefore present an attractive model for studying tumor-host interactions. T cell functional ability is linked to proper signal transduction via T cell receptor (TCR-CD3 complex), especially its zeta chain. The latter has been found to be often depressed in malignancy. Aim of this study was to assess alterations of zeta chain expression and its relation to apoptosis of T lymphocytes. T lymphocytes obtained from pleural effusions of 20 cancer patients and 9 patients with nonmalignant effusions serving as a control were studied. The analysis was performed using flow cytometry combining CD3, CD 4, CD8, CD 16/56, TCR-zeta and TUNEL reaction. In the control group, T lymphocytes obtained from pure lymphocyte effusions had constantly high level of zeta chain while those from malignant pleural effusions had a decreased zeta chain expression. Lymphocytes with low zeta chain expression were the main subpopulation of T cells undergoing apoptosis.
AuthorsJan Sikora, Jan Zeromski
JournalFolia histochemica et cytobiologica (Folia Histochem Cytobiol) Vol. 40 Issue 4 Pg. 347-51 ( 2002) ISSN: 0239-8508 [Print] Poland
PMID12502185 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • CD3 Complex
  • CD4 Antigens
  • CD8 Antigens
  • Membrane Proteins
  • Receptors, Antigen, T-Cell
  • antigen T cell receptor, zeta chain
Topics
  • Apoptosis
  • CD3 Complex (analysis)
  • CD4 Antigens (analysis)
  • CD8 Antigens (analysis)
  • Flow Cytometry (methods)
  • Humans
  • Lymphocytes, Tumor-Infiltrating (immunology, pathology)
  • Membrane Proteins (metabolism)
  • Pleural Effusion, Malignant (immunology, pathology)
  • Receptors, Antigen, T-Cell (metabolism)
  • T-Lymphocyte Subsets (immunology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: